NEWARK, Del., Dec. 3, 2025 /PRNewswire/ -- Future Market Insights (FMI) today announced new findings from its latest flagship report on the GLP-1 Receptor Agonist Market, highlighting powerful growth momentum as pharmaceutical manufacturers accelerate innovation in metabolic and diabetes care. With global diabetes prevalence reaching record highs and healthcare systems shifting toward long-term disease management, GLP-1 receptor agonists continue to emerge as a transformative drug class for both glycemic control and weight management.
According to FMI's updated outlook, the GLP-1 receptor agonist market is projected to surge from USD 2.6 billion in 2025 to USD 7.8 billion by 2035, registering a robust 11.7% CAGR. The expansion is strongly supported by next-generation formulations, extended-release delivery systems, and the rapid clinical adoption of GLP-1 agents beyond diabetes-particularly in obesity and cardiovascular risk reduction.
Manufacturers Accelerate Innovation as Demand for Metabolic Therapies Intensifies
Pharmaceutical manufacturers are rapidly advancing self-administration devices, parenteral innovations, and combination therapies to elevate patient adherence and treatment outcomes. The industry is experiencing:
- A pronounced shift toward once-weekly or extended-interval dosing
- Clinical pipeline expansion targeting obesity, cardiovascular protection, and metabolic syndrome
- Improved injectables with auto-injectors and pre-filled pens
- Rising number of generics and biosimilars as patents expire
"GLP-1 receptor agonists have evolved from single-indication diabetes drugs to multi-benefit metabolic therapies," said an FMI spokesperson. "Manufacturers investing in delivery innovation, stability optimization, and oral alternatives are expected to lead the next decade of growth."
Exenatide Remains the Market Leader in 2025
Exenatide continues to command 24.4% of the drug-class share, supported by its strong safety record, clinical familiarity, and availability in both short-acting and extended-release forms. Increasing generic penetration is unlocking new affordability and accessibility, enabling wider adoption in emerging markets.
Parenteral Formulations Dominate with 63.2% Share
Parenteral delivery remains the gold standard due to optimal bioavailability for peptide-based therapies. Manufacturers' ongoing advancements in long-acting injectables and user-friendly pen devices are expected to maintain the segment's leading position over the decade.
Diabetes: The Core Indication with 59% Market Share
With nearly 90% of global diabetes cases attributed to type 2 diabetes, the demand for GLP-1 receptor agonists continues to grow rapidly. Their proven efficacy in:
- lowering HbA1c
- supporting weight reduction
- reducing cardiovascular complications
positions them as a cornerstone in modern diabetes treatment guidelines. Improved insurance coverage and early-diagnosis initiatives are driving prescription volumes across major markets
Regional Growth Outlook: India and China Lead the Global Acceleration
FMI's country-wise analysis shows exceptional growth potential:
Country | Forecast CAGR (2025-2035) |
India | 24.70 % |
China | 23.10 % |
United Kingdom | 12.10 % |
China
With urbanization, lifestyle shifts, and healthcare reforms, China's diabetic population is among the world's largest. Accessibility to advanced GLP-1 therapies continues improving under government-led healthcare expansion.
India
India represents the world's fastest-growing metabolic medicine market. High genetic predisposition, rising obesity rates, and improved awareness of early diabetes management are generating extraordinary demand for GLP-1 therapies.
United Kingdom
With a mature healthcare ecosystem, the UK continues to expand access through NHS coverage and proactive preventive-care programs.
Competitive Landscape: Manufacturers Strengthen Pipelines Amid Global Demand
Leading companies are focusing on clinical trials exploring cardiovascular outcomes, beta-cell preservation, and novel GLP-1/GLP-2 combinations. Major players include:
- Novo Nordisk A/S
- Eli Lilly and Company
- Sanofi
- AstraZeneca
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd.
- Amgen, Inc.
- Innovent Biologics, Inc.
- PegBio Co., Ltd
- Boehringer Ingelheim International GmbH
- Others
Request Full Report Sample pages -https://www.futuremarketinsights.com/reports/sample/rep-gb-12346
Recent Innovations and Market-Shaping Developments
- June 24, 2025: Eli Lilly introduced Orforglipron, a first-in-class oral non-peptide GLP-1 with promising Phase-2 outcomes.
- October 22, 2025: Scientific Reports published novel long-acting chimeric GLP-1 molecules engineered with DARPin fusions.
- November 4, 2025: University of Tabriz researchers announced a breakthrough long-acting GLP-1 agonist candidate.
- August 2025: Landmark uptake of Ozempic, Wegovy, and Mounjaro reshaped the metabolic-care landscape, triggering surging market valuations for leading manufacturers.
Market Challenges
Despite strong momentum, FMI highlights several barriers:
- High treatment costs affecting patient access
- GI-related side effects during early therapy
- Preference for oral alternatives among certain patient groups
- Regulatory complexity for next-gen molecules
- Limited awareness in developing region
About the Report
FMI's GLP-1 Receptor Agonist Market Report covers:
- Top GLP-1 drugs globally
- Demand for oral GLP-1 therapies
- Comparison between Semaglutide and Ozempic
- GLP-1 mechanisms, GLP-1 vs. GLP-2 studies
- Market segmentation across drug class, indication, delivery route, and channel
- Regional and country-level forecasts through 2035
The complete report is available for access upon purchase FMI Lucrative Dashboard -
https://www.futuremarketinsights.com/checkout/12346
For Yearly Subscription Please Contact us here - sales@futuremarketinsights.com
New Report on GLP - 1 along with Healthcare Trending Report-
- GLP-1 Diabetes Treatment Drugs Market - https://www.futuremarketinsights.com/reports/glp-1-diabetes-treatment-drugs-market
- GLP-1 Nutritional Support Market - https://www.futuremarketinsights.com/reports/glp-1-nutritional-support-market
- Obesity GLP-1 Market - https://www.futuremarketinsights.com/reports/obesity-glp-1-market
- OX40 Receptor Agonist Market - https://www.futuremarketinsights.com/reports/ox-40-receptor-agonist-market
- Short-Acting Beta-Agonists Market - https://www.futuremarketinsights.com/reports/short-acting-beta-agonists-market
- Peptide Receptor Radionuclide Therapy (PRRT) Market - https://www.futuremarketinsights.com/reports/peptide-receptor-radionuclide-therapy-prrt-market
- Fibroblast Growth Factor Receptor (FGFR) Inhibitor Market - https://www.futuremarketinsights.com/reports/fibroblast-growth-factor-receptor-inhibitor-market
- Long-Acting Beta-Agonists Market - https://www.futuremarketinsights.com/reports/long-acting-beta-agonists-market
- Chimeric Antigen Receptor (CAR) T-Cell Therapy Market - https://www.futuremarketinsights.com/reports/chimeric-antigen-receptor-t-cell-therapy-market
Why FMI - https://www.futuremarketinsights.com/why-fmi
FMI iDEA Methodology - https://www.futuremarketinsights.com/methodology
About FMI (Future Market Insights, Inc.):
Future Market Insights (FMI) is a leading provider of market intelligence, offering in-depth research across pharmaceuticals, healthcare, biotechnology, and life sciences. With a global research network and advanced analytical frameworks, FMI supports manufacturers, investors, policymakers, and stakeholders in making informed strategic decisions.
Media Contact
Rahul Singh
AVP - Marketing and Growth Strategy
Future Market Insights, Inc.
+91 702-892-0828
For Sales - sales@futuremarketinsights.com
For Media - Rahul.singh@futuremarketinsights.com
Logo: https://mma.prnewswire.com/media/1197648/3531122/FMI_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/fmi-reports-strong-11-7-cagr-growth-outlook-for-the-glp-1-receptor-agonist-market-through-2035--302631818.html
